Tonix Pharmaceuticals (TNXP) - 2025 Q4 - Annual Report

Drug Approvals and Launches - TONMYA received FDA approval for the treatment of fibromyalgia in adults on August 15, 2025, and was launched on November 17, 2025[16]. - Tonix received FDA approval for TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia, marking the first new treatment in over 15 years[70]. - The company launched TONMYA in the U.S. on November 17, 2025, which addresses core symptoms of fibromyalgia including pain, disturbed sleep, and fatigue[70]. Clinical Development Pipeline - The company has a diversified pipeline with multiple programs in clinical and preclinical development, including TNX-102 SL for major depressive disorder, which is expected to enter Phase 2 in mid-2026[19]. - TNX-1500, aimed at preventing kidney transplant rejection, is Phase 2-ready with a study expected to start in mid-2026[20]. - The company plans to initiate a Phase 2 study for TNX-2900, targeting Prader-Willi syndrome, in Q1 2027[21]. - TNX-1300, for cocaine intoxication, is currently in Phase 2 and has received Breakthrough Therapy designation from the FDA[20]. - TNX-1900 is being developed for binge eating disorder, adolescent obesity, and other CNS disorders through investigator-initiated studies at Massachusetts General Hospital[36]. - TNX-4800, a long-acting monoclonal antibody for Lyme disease, showed 95% effectiveness in preventing infection after 6 days of exposure to infected ticks; plans for Phase 2 studies are set for 2026 and 2028[39][40]. - TNX-2900, for Prader-Willi syndrome, received Orphan-Drug Designation and IND clearance in late 2023, with a Phase 2 study planned to begin in Q1 2027[48][49]. - TNX-102 SL is expected to enter Phase 2 for MDD in mid-2026, with a pivotal study enrolling approximately 360 patients across 30 U.S. sites[86]. - The OASIS trial, funded by a $3 million DoD grant, aims to investigate TNX-102 SL's efficacy in reducing adverse effects of acute trauma[88]. Market Strategy and Commercialization - The company aims to commercialize TONMYA for fibromyalgia, launched in November 2025, with approximately 90 U.S. sales representatives promoting it to healthcare providers[52]. - The company has established commercial operations and is focused on expanding TONMYA's market presence through lifecycle management strategies[27]. - The commercialization strategy for TONMYA includes a targeted sales approach with approximately 90 field sales representatives as of December 31, 2025[138]. - Tonix has implemented a market access strategy to support patient access to TONMYA across key payer segments, including commercial plans and government programs[141]. Intellectual Property and Patent Strategy - Tonix is pursuing a broad intellectual property strategy to protect its product candidates, including patents for TONMYA's composition and methods of use[55]. - The patent portfolio includes 45 issued U.S. patents and 46 issued non-U.S. patents as of March 5, 2026, with additional applications in progress[160]. - The company is actively pursuing 22 U.S. non-provisional patent applications and 238 non-U.S./non-PCT patent applications to strengthen its intellectual property position[160]. - TNX-102 SL has received U.S. market exclusivity for PTSD treatment until 2030, based on U.S. Patent No. 9,918,948[172]. - TNX-102 SL has European market exclusivity for depression treatment until March 2032, as per European patent 2,683,245[180]. Competitive Landscape - The U.S. fibromyalgia market has seen the introduction of TONMYA, the first new treatment in over 15 years, approved in August 2025, targeting non-restorative sleep[145]. - As of 2026, the U.S. fibromyalgia therapeutic landscape includes four FDA-approved treatments, with the first three being pregabalin, duloxetine, and milnacipran, which have been the standard of care since 2007-2009[145]. - Axsome Therapeutics initiated a Phase 3 trial of AXS-14 for fibromyalgia management in January 2026, indicating ongoing competition in the sector[146]. - The competitive landscape for migraine treatments has expanded with the FDA approval of Axsome Therapeutics' Symbravo and Satsuma Pharmaceuticals' Atzumi in 2025, highlighting increased innovation[148]. Research and Development Facilities - The company operates a 48,000 square foot RDC in Frederick, Maryland, and a 45,000 square foot ADC in Dartmouth, Massachusetts, for research and manufacturing of vaccines and biologics[50]. - The Advanced Development Center in Dartmouth, MA, is equipped for GMP production of live-virus vaccines and biologics, ready for reactivation by 2027 or in case of emergencies[132]. Specific Drug Developments - TNX-1300 is a recombinant protein enzyme that catalyzes the breakdown of cocaine, offering a targeted approach to cocaine intoxication management[102]. - TNX-801 is a potential smallpox and mpox vaccine with improved tolerability and efficacy compared to existing vaccines, requiring only a single dose for durable protection[121][122]. - TNX-4900, a selective S1R antagonist, has shown significant analgesic activity in preclinical models, with a Ki of 7.5 nM and oral bioavailability of approximately 28%[129]. - TNX-1700 has shown efficacy in preclinical studies for gastric and colorectal cancers, demonstrating tumor reduction and increased survival rates[116].